Publicaciones en colaboración con investigadores/as de Princess Margaret Hospital (7)

2020

  1. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

2017

  1. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

    European Journal of Haematology, Vol. 99, Núm. 3, pp. 199-206

2015

  1. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

    Haematologica, Vol. 100, Núm. 10, pp. 1327-1333

  2. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

    Haematologica, Vol. 100, Núm. 10, pp. 1334-1339

2009

  1. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

    British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903

2007

  1. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial

    Blood, Vol. 110, Núm. 10, pp. 3557-3560

2005

  1. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 352, Núm. 24, pp. 2487-2498